June, 2015

Sym004: Truly a New Level of Anti-EGFR Treatment?

Stintzing, S and Heinemann, V.
Cancer Discov; 5(6); 578–80, 2015
January 22, 2015

Research Article Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance

Pedersen MW, Jacobsen HJ, Koefoed K, Dahlman A, Kjær I, Poulsen TT, Meijer PJ, Nielsen LS, Horak ID, Lantto J, Kragh M
AACR, 2015
December, 2013

Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers

Huang S, Peet CR, Saker J, Li C, Armstrong EA, Kragh M, Pedersen MW, Harari PM.
Mol Cancer Ther. 2013 Dec;12(12):2772-81
October, 2013

Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab

Iida M, Brand TM, Starr MM, Li C, Huppert EJ, Luthar N, Pedersen MW, Horak ID, Kragh M, Wheeler DL.
Neoplasia. 2013 Oct;15(10):1196-206
July 28, 2012

Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia

Robak T, Windyga J, Trelinski J, von Depka Prondzinski M, Giagounidis A, Doyen C, Janssens A, Álvarez-Román MT, Jarque I, Loscertales J, Rus GP, Hellmann A, Jedrzejczak WW, Kuliczkowski K, Golubovic LM, Celeketic D, Cucuianu A, Gheorghita E, Lazaroiu M, Shpilberg O, Attias D, Karyagina E, Svetlana K, Vilchevska K, Cooper N, Talks K, Prabhu M, Sripada P, Bharadwaj TPR, Næsted H, Skartved NJØ, Frandsen TP, Flensburg MF, Andersen PS, Petersen J
Blood, 2012, 120, 3627-3628
November, 2011

Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor

Koefoed K, Steinaa L, Søderberg JN, Kjær I, Jacobsen HJ, Meijer PJ, Haurum J, Jensen A, Kragh M, Andersen PS, Pedersen MW.
Landes Bioscience, 2011, 3:6, 584-595
October 15, 2011

Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans

Poulsen TR, Jensen A, Haurum JS, Andersen PS
J Immunol., 2011, 187:8, 4229-4235
September 15, 2011

Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor

Skartved NJ, Jacobsen HJ, Pedersen MW, Jensen PF, Sen JW, Hey A, Kragh M
Clin Cancer Res., 2011, 17:18, 5962-5972
Read more about our mAb mixtures